Parkinson Disease
Conditions
Keywords
blood, biomarker, Parkinson's disease
Brief summary
Currently, there are no cures or disease modifying therapies for Parkinson's disease (PD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for PD. Several detection parameters will be assessed through enrollment of Parkinson's patients and age matched healthy volunteers over 50 years of age to learn more about the analytical process and biological variability.
Interventions
None listed
Sponsors
Duke University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Inclusion Age matched to PD patient Parkinson's Disease Patients: * 50 years and older * PD patient who is seen at the Duke Movement Disorders Center * Early PD diagnosis (Hoehn and Yahr scale ≤ 3) * Non-smoking * No cancer treatment in the last 5 years * Able to read and speak English Healthy Control Participants: * 50 years and older * Non-smoking * No cancer treatment in the last 5 years * Able to read and speak English
Exclusion criteria
Parkinson's Disease Patients: * Known additional neurological disease * Clinical trial intervention within the last 6 months Healthy Control Participants: * Neurological degenerative diseases (such as Parkinson's, Alzheimer's or Huntington's) * Clinical trial intervention within the last 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biological marker of Parkinson's disease | Day 1 | Test for biological marker of Parkinson's disease, mtDNA damage |
Countries
United States
Outcome results
None listed